[CAS NO. 1948-33-0] TBHQ

Name: TBHQ
Brand: Arctom Scientific
SKU: SLK-S4990

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1948-33-0]

Store

Catalog

SLK-S4990

Brand

Selleck

CAS

1948-33-0

DESCRIPTION [1948-33-0]

Overview

MDL	MFCD00002344
Molecular Weight	166.22
Molecular Formula	C10H14O2
SMILES	C(C)(C)(C)C1=C(O)C=CC(O)=C1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	6.0161 mL	30.0806 mL	60.1612 mL
5 mM	1.2032 mL	6.0161 mL	12.0322 mL
10 mM	0.6016 mL	3.0081 mL	6.0161 mL
50 mM	0.1203 mL	0.6016 mL	1.2032 mL

Description

Tert-butylhydroquinone (TBHQ) is an compound which is used to prevent lipid peroxidation and shows multiple cytoprotective actions. It is an activator of .

Targets

Nrf2 ^[1]

In vitro

Tert-butylhydroquinone (tBHQ) is a metabolite of the chemical compound butylated hydroxyanisole and induces Nrf2 activation and conveys protection against hydrogen peroxide, 6-hydroxydopamine, the pesticidal deltamethrin, and other toxicants. tBHQ preferentially alters the redox status in the mitochondrial compartment in HeLa cells. HeLa cells treated with tBHQ show a preferential oxidation of mitochondrial thioredoxin-2 (Trx2), while cellular glutathione and cytosolic thioredoxin-1 are not affected. In cultured H9c2 cells and primary cardiac myocytes, TBHQ stimulates Akt phosphorylation and suppresses oxidant-induced apoptosis.

In vivo

TBHQ treatment elicits significant cytoprotective actions in different organs under pathological conditions. Systemic or local intra-cerebroventricular treatment with TBHQ in an ischemic stroke model in rats significantly reduces the infarct size and neurological deficits. Administration of TBHQ in rats suppresses renal damage and oxidative stress after ischemia and reperfusion injury. In mice with type 1 diabetes, chronic treatment with TBHQ significantly reduces the degree of glomerular fibrosis and ameliorates proteinuria. TBHQ treatment prevents left ventricular dilatation and cardiac dysfunction induced by transverse aortic constriction (TAC), and decreases the prevalence of myocardial apoptosis. The beneficial effects of TBHQ are associated with an increase in Akt activation, but not related to activations of Nrf2 or AMP-activated protein kinase. TBHQ-induced Akt activation is accompanied by increased phosphorylation of Bad, glycogen synthase kinase-3β (GSK-3β) and mammalian target of rapamycin (mTOR).

References

[1] Imhoff BR, et al. Cell Biol Toxicol. 2010, 26(6):541-51.
[2] Yongtao Zhang, et al. Sci Rep. 2015, 5: 13005.

Synonyms

1,4-Benzenediol, 2-(1,1-dimethylethyl)-

Hydroquinone, tert-butyl-

2-(1,1-Dimethylethyl)-1,4-benzenediol

tert-Butylhydroquinone

2-tert-Butylhydroquinone

Mono-tert-butylhydroquinone

tert-Butyl-1,4-benzenediol

TBHQ

MTBHQ

Mono-tertiarybutylhydroquinone

t-Butylhydroquinone

2-tert-Butyl-1,4-benzenediol

2-(1,1-Dimethylethyl)hydroquinone

2-(tert-Butyl)-p-hydroquinone

Banox 20BA

Tenox TBHQ

2-tert-Butyl-1,4-hydroquinone

2-tert-Butyl-1,4-dihydroxybenzene

t-Butylhydroquinone

Tenox 20

NSC 4972

Keniox 20

tert-Butyldihydroxybenzene

2-t-Butylhydroquinone

MC-TB 20

Grindox 450

Grindox 204

tert-Butyl-1,4-dihydroxybenzene

2-tert-Butyl-4-hydroxyphenol

Stearer TBH

PI 172